AU2012382929A1 - Novel cabergoline derivatives - Google Patents

Novel cabergoline derivatives Download PDF

Info

Publication number
AU2012382929A1
AU2012382929A1 AU2012382929A AU2012382929A AU2012382929A1 AU 2012382929 A1 AU2012382929 A1 AU 2012382929A1 AU 2012382929 A AU2012382929 A AU 2012382929A AU 2012382929 A AU2012382929 A AU 2012382929A AU 2012382929 A1 AU2012382929 A1 AU 2012382929A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
compound
hydrogen
fluorine atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012382929A
Other languages
English (en)
Inventor
Thomas A. Armer
Jian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAP Pharmaceuticals Inc
Original Assignee
MAP Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAP Pharmaceuticals Inc filed Critical MAP Pharmaceuticals Inc
Publication of AU2012382929A1 publication Critical patent/AU2012382929A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2012382929A 2012-06-22 2012-06-22 Novel cabergoline derivatives Abandoned AU2012382929A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043687 WO2013191704A1 (en) 2012-06-22 2012-06-22 Novel cabergoline derivatives

Publications (1)

Publication Number Publication Date
AU2012382929A1 true AU2012382929A1 (en) 2015-02-05

Family

ID=49769156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012382929A Abandoned AU2012382929A1 (en) 2012-06-22 2012-06-22 Novel cabergoline derivatives

Country Status (11)

Country Link
EP (1) EP2863747A4 (zh)
JP (1) JP2015525239A (zh)
CN (1) CN104822264A (zh)
AU (1) AU2012382929A1 (zh)
BR (1) BR112014031945A2 (zh)
CA (1) CA2876321A1 (zh)
HK (1) HK1208997A1 (zh)
IL (1) IL236310A0 (zh)
RU (1) RU2014153672A (zh)
SG (1) SG11201408567PA (zh)
WO (1) WO2013191704A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428745A (zh) * 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
CN106866656A (zh) * 2017-02-28 2017-06-20 西南交通大学 一类麦角碱衍生物及其在预防和治疗精神疾病的用途
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DK338789A (da) * 1988-07-15 1990-01-16 Schering Ag 2-substituerede ergolinylurinstofderivater og fremgangsmaade til fremstilling deraf, deres anvendelse som laegemidler samt mellemprodukter til fremstilling deraf
DE3913756A1 (de) * 1989-04-21 1990-10-25 Schering Ag 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung
WO1995005176A1 (en) * 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
CZ287176B6 (cs) * 1997-10-03 2000-10-11 Galena A. S. Způsob přípravy ergolinových derivátů
EP1592424A1 (en) * 2003-02-05 2005-11-09 Pharmacia Italia S.p.A. Cabergoline for the prophylactic treatment of migraine
GB0307377D0 (en) * 2003-03-31 2003-05-07 Merad Pharmaceuticals Ltd Ergoline derivatives
HUP0400517A3 (en) * 2004-03-04 2006-05-29 Richter Gedeon Vegyeszet Process for producing cabergoline
WO2006097345A1 (en) * 2005-03-17 2006-09-21 Synthon Argentina S.A. Improved process for making cabergoline
GB0511060D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
WO2010081036A2 (en) * 2009-01-09 2010-07-15 President And Fellows Of Harvard College Fluorine containing compounds and methods of use thereof
AU2010237100A1 (en) * 2009-04-15 2011-10-27 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as Alzheimer's disease
CA2859175A1 (en) * 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds

Also Published As

Publication number Publication date
EP2863747A4 (en) 2015-12-23
BR112014031945A2 (pt) 2017-06-27
WO2013191704A1 (en) 2013-12-27
JP2015525239A (ja) 2015-09-03
IL236310A0 (en) 2015-02-26
HK1208997A1 (zh) 2016-03-24
EP2863747A1 (en) 2015-04-29
CA2876321A1 (en) 2013-12-27
RU2014153672A (ru) 2016-08-10
CN104822264A (zh) 2015-08-05
SG11201408567PA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
US8933093B2 (en) Fluoroergoline analogs
US10308651B2 (en) Ergoline compounds and uses thereof
US9012640B2 (en) Cabergoline derivatives
US8946420B2 (en) Neuromodulatory compounds
US8969374B2 (en) Iso-ergoline derivatives
US9815830B2 (en) Isoergoline compounds and uses thereof
AU2012382929A1 (en) Novel cabergoline derivatives

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application